表紙
市場調査レポート

Amitiza (過敏性腸症候群治療薬) - 2023年までの予測と市場分析

Amitiza (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 325974
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
Amitiza (過敏性腸症候群治療薬) - 2023年までの予測と市場分析 Amitiza (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
出版日: 2014年12月31日 ページ情報: 英文 45 Pages
概要

当レポートでは、過敏性腸症候群の治療薬であるAmitizaについて調査しており、過敏性腸症候群の概要や治療薬の競合動向、製品情報、売上予測などを提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
  • 分類
  • 症状
  • 予後
  • 生活の質 (QOL)

第4章 疾患の管理

  • 疾患と治療の概要
    • 診断
    • 治療ガイドラインと主な処方薬
    • 臨床診療

第5章 競合評価

  • 概要

第6章 Amitiza (ルビプロストン)

  • 概要
  • 有効性
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

目次
Product Code: GDHC517DFR

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

Amitiza (lubiprostone) is indicated for the treatment of IBS-C in women 18 years of age and older, but only in the US. This product was developed by Sucampo Pharmaceuticals and Takeda, and initially gained approval in the US in 2006 for the treatment of chronic idiopathic constipation (CIC) in adults. In 2008, Amitiza gained a label expansion from the Food and Drug Administration (FDA) for the treatment of IBS-C in women of 18 years of age and older.

Scope

  • Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Amitiza including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Amitiza for the top 2 countries from 2013 to 2023.
  • Sales information covered for the US and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for IBS.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Amitiza performance.
  • Obtain sales forecast for Amitiza from 2013-2023 in top 2 countries (the US and Japan).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Amitiza (lubiprostone)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety

6.4. SWOT Analysis

  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed IBS Patients
    • 7.4.2. General Pricing Assumptions
    • 7.4.3. Individual Drug Assumptions
    • 7.4.4. Generic Erosion
  • 7.5. Primary Research - KOLs Interviewed for This Report
  • 7.6. Primary Research - Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Analyst
    • 7.7.2. Therapy Area Director
    • 7.7.3. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: Common Symptoms of IBS
  • Table 2: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS
  • Table 3: Treatment Guidelines for IBS
  • Table 4: Leading Prescribed Drugs for IBS by Predominant Symptoms in the 7MM, 2014†
  • Table 5: Leading Branded Treatments for IBS, 2014
  • Table 6: Product Profile - Amitiza
  • Table 7: Safety of Amitiza - Most Frequently Reported Adverse Events
  • Table 8: Amitiza SWOT Analysis, 2014
  • Table 9: Global IBS Sales Forecasts ($m) for Amitiza, 2013-2023
  • Table 10: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Summary of Pharmacotherapies Used to Treat IBS
Back to Top